Index

Show indicators by:

  • Cancer Control Domain
  • Disease Site
  • Dashboard
  • Disease Site
    • Breast
      • Breast cancer screening
      • Screening in underserved populations
      • Breast cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Breast cancer resections that are mastectomies
        • The use of breast-conserving surgery versus mastectomies for breast cancer resections
      • Radiation therapy
        • Post-operative radiation therapy for stage I or II breast cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Breast cancer screening outside recommended guidelines
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Colorectal
      • Colorectal cancer screening
      • Geographic variation in colorectal cancer risk
      • Screening in underserved populations
      • Colorectal cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Removal and examination of 12 or more lymph nodes in colon resections
        • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
      • Radiation therapy
        • Pre-operative radiation therapy for patients with stage II or III rectal cancer
      • Post-operative chemotherapy for stage III colon cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Lung
      • Capture of stage
      • Stage distribution
      • Geographic variation in lung cancer risk
      • Resection rates for stage II or IIIA Non-snmall cell lung cancer patients
      • Post-operative chemotherapy for stage II or IIIA non-small cell lung cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Prostate
      • PSA testing
      • Prostate risk profile
      • Capture of stage
      • Stage distribution
      • Prostate wait times for surgery
      • Prostate wait times for radiation therapy
      • Radical prostatectomy: open versus laparoscopic surgery
      • Prostate patterns of care: radiation and surgical treatment
      • Prostate access to palliative radiation
      • Prostate clinical trials participation
      • Adult clinical trial participation
      • Prostate cancer research investment
      • Cancer research investment
      • Incidence & Mortality Rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Cervical
      • Human papillomavirus (HPV) vaccination
      • Cervical cancer screening
      • Screening in underserved populations
    • Pancreas
      • Incidence and mortality rates
    • Stage Distribution
  • Province & Territory
  • 1. Prevention
  • 2. Screening
  • 3. Diagnosis
  • 4. Treatment
  • 5. Person-Centred Perspective
  • 6. Research
  • 7. Appropriateness
  • 8. Long-term outcomes
  • Smoking prevalence
  • Smoking behaviours in current cancer patients
  • Smoking cessation
  • Second-hand smoke exposure
  • Geographic variation in lung cancer risk
  • Alcohol consumption
  • Adult overweight and obesity
  • Active transportation
  • Physical inactivity
  • Human papillomavirus (HPV) vaccination
  • Fruit and vegetable consumption
  • Geographic variation in colorectal cancer risk
  • Cervical cancer screening
  • Breast cancer screening
  • Colorectal cancer screening
  • PSA testing
  • Screening in underserved populations
  • Breast cancer diagnosis wait times
  • Colorectal cancer diagnosis wait times
  • Capture of stage
  • Stage distribution
  • Prostate risk profile
  • Surgery
  • Radiation therapy
  • Systemic therapy
  • Removal and examination of 12 or more lymph nodes in colon resections
  • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
  • The use of breast-conserving surgery versus mastectomies for breast cancer resections
  • Breast cancer resections that are mastectomies
  • High-risk, resource-intensive surgeries for esophageal, pancreatic, liver, lung and ovarian cancers in Canada
  • Prostate wait times for surgery
  • Radical prostatectomy: open versus laparoscopic surgery
  • Radiation therapy wait times
  • Radiation therapy utilization and capacity
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer
  • Post-operative radiation therapy for patients with stage I or II breast cancer
  • Prostate wait times for radiation therapy
  • Prostate patterns of care: radiation and surgical treatment
  • Post-operative chemotherapy for stage III colon cancer patients
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer
  • Screening for distress
  • Patient satisfaction
  • Place of death
  • Prostate access to palliative radiation
  • Adult clinical trial participation
  • Prostate clinical trials participation
  • Pediatric clinical trial participation
  • Cancer research investment
  • Prostate cancer research investment
  • Breast cancer screening outside of guidelines
  • Breast cancer mastectomies done as day surgery
  • Intensive care use in the last two weeks of life
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Pancreatic cancer
  • Five-year net survival by income quintile for several cancers in Canada
System Performance Logo
System Performance
  • About
  • Reports
  • Français
  • Home
  • Cancer control domain
  • 7. Appropriateness
  • Breast cancer screening outside of guidelines

Breast cancer screening outside of guidelines

  • Charts and Tables

    Charts and Tables

    Figure 7.1

    Percentage of self-reported screening mammograms performed in asymptomatic† women within and outside the recommended target age range for screening in the past two years, by province/‌territory — 2012 reporting year

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    † An asymptomatic woman is deemed to have had screening mammography if her reason for undergoing a mammogram was one of the following: family history of breast cancer, regular check-up/‌routine screening, age or current use of hormone replacement therapy.

    E Interpret with caution owing to large variability in the estimate.

    * Suppressed owing to small numbers.

    Data source: Statistics Canada, Canadian Community Health Survey.

    Data Table

    Jurisdiction Age group MammogramPercent (%)Quality Indicator Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    YTWithin guidelines: 50–744786.576.196.9
    YTOutside guidelines: 35–49 or 75+2013.5E819
    NBWithin guidelines: 50–7443484.379.389.2
    NBOutside guidelines: 35–49323.6E2.15.1
    NBOutside guidelines: 75+4312.1E717.3
    QCWithin guidelines: 50–741,86182.579.385.8
    QCOutside guidelines: 35–491445.94.67.2
    QCOutside guidelines: 75+13611.58.115
    SKWithin guidelines: 50–7447478.472.784
    SKOutside guidelines: 35–49898.66.310.9
    SKOutside guidelines: 75+4413E6.919.1
    MBWithin guidelines: 50–7447774.967.482.3
    MBOutside guidelines: 35–49646.7E4.19.3
    MBOutside guidelines: 75+4018.4E10.526.4
    ONWithin guidelines: 50–743,30074.271.477
    ONOutside guidelines: 35–4947775.98
    ONOutside guidelines: 75+40818.915.921.8
    NSWithin guidelines: 50–7435273.165.880.4
    NSOutside guidelines: 35–49394.9E2.87
    NSOutside guidelines: 75+6222E14.429.6
    NLWithin guidelines: 50–7429573.165.381
    NLOutside guidelines: 35–49336.2E3.78.7
    NLOutside guidelines: 75+5420.7E12.428.9
    ABWithin guidelines: 50–7483271.766.876.6
    ABOutside guidelines: 35–491035.446.8
    ABOutside guidelines: 75+14722.917.828
    BCWithin guidelines: 50–741,09170.266.374
    BCOutside guidelines: 35–491597.45.89
    BCOutside guidelines: 75+22222.518.326.6
    PEWithin guidelines: 50–7413666.456.676.3
    PEOutside guidelines: 35–49167.2E3.311.2
    PEOutside guidelines: 75+1826.3E15.736.9
    NTWithin guidelines: 50–744662.349.575.2
    NTOutside guidelines: 35–49 or 75+2737.7E24.850.5
    NUWithin guidelines: 50–74*****
    NUOutside guidelines: 35–49*****
    NUOutside guidelines: 75+*****

    + Expand Table

    † An asymptomatic woman is deemed to have had screening mammography if her reason for undergoing a mammogram was one of the following: family history of breast cancer, regular check-up/‌routine screening, age or current use of hormone replacement therapy.

    E Interpret with caution owing to large variability in the estimate.

    * Suppressed owing to small numbers.

    Data source: Statistics Canada, Canadian Community Health Survey.

    Figure 7.5

    Percentage of all screening mammograms† in the past year reported by women aged 40–49, by jurisdiction‡ — 2008–12 reporting years combined

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    E Interpret with caution owing to large variability in the estimate.

    * Suppressed owing to small numbers.

    † A woman is deemed to have had screening mammography if her reason for undergoing a mammogram was one of the following: family history of breast cancer, regular check-up/routine screening, age, or current use of hormone replacement therapy.

    ‡ All jurisdictions provided data in 2008 and 2012. Screening content was optional in 2009–11 and the following jurisdictions provided data: 2009: AB, NB, NS, NL, NT; 2010: AB, NB, NS, NL, NT; 2011: AB, ON, NL, NU.

    Data source: Statistics Canada, Canadian Community Health Survey.

    Data Table

    JurisdictionNumber of women having had screening mammogramsPercent (%)Quality indicatorLower bound of 95% confidence intervalUpper bound of 95% confidence interval
    MB5,4017.0E2.811.2
    QC64,48311.9E7.016.7
    SK9,17514.7E7.721.7
    NB32,91317.612.922.2
    ON387,30818.315.621.0
    BC98,38725.920.930.8
    PE3,30626.9E14.039.7
    NL54,56026.922.131.6
    NS66,38227.422.132.8
    AB311,01027.523.831.2
    NT2,29627.6E17.937.3
    YT*****
    NU*****

    + Expand Table

    E Interpret with caution owing to large variability in the estimate.

    * Suppressed owing to small numbers.

    † A woman is deemed to have had screening mammography if her reason for undergoing a mammogram was one of the following: family history of breast cancer, regular check-up/routine screening, age, or current use of hormone replacement therapy.

    ‡ All jurisdictions provided data in 2008 and 2012. Screening content was optional in 2009–11 and the following jurisdictions provided data: 2009: AB, NB, NS, NL, NT; 2010: AB, NB, NS, NL, NT; 2011: AB, ON, NL, NU.

    Data source: Statistics Canada, Canadian Community Health Survey.

    Figure 7.6

    Proportion of self-reported screening mammograms† performed on women within and outside the recommended target age (50-74) in the past year, jurisdictions combined‡ — 2008, 2012 and 2014 reporting years

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    † A woman is deemed to have had a screening mammogram if her reason for undergoing a mammogram was one of the following: family history of breast cancer, regular check-up/routine screening, age or current use of hormone replacement therapy.

    ‡ Includes NS, NB, AB and NT

    The percentages might not sum up to 100% due to rounding methodology adopted by Statistics Canada.

    Data source: Statistics Canada, Canadian Community Health Survey.

    Data Table

    YearAge groupNumber of women having had screening mammogramsPercent (%)Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    200875+26,5006.45.08.1
    200850-74265,50064.059.068.0
    200840-49123,50030.025.034.0
    201275+20,5004.93.76.4
    201250-74304,25073.068.078.0
    201240-4991,25022.017.427.0
    201475+29,0007.25.49.6
    201450-74296,60074.068.078.0
    201440-4977,00019.114.824.0

    + Expand Table

    † A woman is deemed to have had a screening mammogram if her reason for undergoing a mammogram was one of the following: family history of breast cancer, regular check-up/routine screening, age or current use of hormone replacement therapy.

    ‡ Includes NS, NB, AB and NT

    The percentages might not sum up to 100% due to rounding methodology adopted by Statistics Canada.

    Data source: Statistics Canada, Canadian Community Health Survey.

  • Data specifications

    Data specifications

    Definition:

    1. The percentage of all screening mammograms in the past year reported by women aged 40 – 49
    2. Distribution of screening mammograms in the past year by age groups

    Rationale for measurement: Screening mammography has been shown to reduce breast cancer morbidity and mortality associated with advanced cancer, but the evidence of benefit is strongest for women between the ages of 50 and 74. Reporting on mammograms performed outside of the recommended age range can help identify how mammogram screening practices across the country can become better aligned with best practice guidelines and recommendations, in order to avoid any unnecessary and potentially harmful interventions.

    Measurement timeframe:

    1. The percentage of all screening mammograms in the past year reported by women aged 40 – 49: years 2008-2012 combined
    2. Distribution of screening mammograms in the past year by age groups: years 2008, 2012 and 2014

    Denominator: The number of women reported having had a screening mammogram in the past year for asymptomatic reasons

    Numerator:

    1. The percentage of all screening mammograms in the past year reported by women aged 40 – 49:
      The number of women aged 40-49 reporting having a screening mammogram in the past one year for asymptomatic reasons
    2. Distribution of screening mammograms in the past year by age groups:
      The number of women reporting having had a screening mammogram in the past one year for asymptomatic reasons, separated by age group:

      • 40-49
      • 50-74
      • 75+

    Exclusion criteria:

    1. Women aged <40 were excluded
    2. Women reporting having had a screening mammogram in the past year for symptomatic reasons were excluded

    Data availability:

    1. The percentage of all screening mammograms in the past year reported by women aged 40 – 49 by jurisdiction: All jurisdictions provided data in 2008 and 2012. Mammography module was optional from 2009 to 2011; the following jurisdictions provided data in 2009: AB, NB, NS, NL and NT; 2010: AB, NB, NS, NL and NT; 2011: AB, ON, NL and NU
    2. Distribution of screening mammograms in the past year by age groups in 2008, 2012 and 2014 includes data from NS, NB, AB and NT

    Stratification:

    1. The percentage of all screening mammograms in the past year reported by women aged 40 – 49: by jurisdiction
    2. Distribution of screening mammograms in the past year: by age group: 40-49, 50-74, 75+

    Data source: Statistics Canada, Canadian Community Health Survey (CCHS)

    Data retrieval date:

    1. The percentage of all screening mammograms in the past year reported by women aged 40 – 49: January 2016
    2. Distribution of screening mammograms in the past year: February 2018

    Variables details: Not applicable

    Notes from jurisdictions: Not applicable

    Methodology notes:

    1. Data were based on a representative sample and was extrapolated to the overall population.
    2. Contents about woman breast cancer mammograms in survey questionnaire are optional, not all jurisdictions have data available across the years from 2008 to 2012
    3. At jurisdiction level, data were pooled through 2008 to 2012 whenever data were available to get the most stable statistical measures of breast screening mammograms in the age 40 – 49;
    4. Jurisdiction combined includes 4 provinces: NS, NB, AB and NT. These provinces have data available across the years (2008, 2012 and 2014) to reflect the time trend of breast screening mammograms by age group, especially for age groups outside of the guideline: 40-49 and 75+.
    5. A woman is deemed to have had screening mammography due to asymptomatic reasons if she self-reported one of the following reasons: family history of breast cancer, regular check-up/routine screening, age, or current use of hormone replacement therapy. Any of the following reasons were not considered screening mammography for asymptomatic reasons: lump, follow-up to breast cancer treatment, breast problem or other.

    Changes to definition compared to previous years: Not applicable

  • Related indicators

    Related Indicators

    Breast cancer screening

    Participation rate in breast cancer screening programs (%), by jurisdiction – 2014 screening year
    View this indicator
    Breast cancer diagnosis wait times

    Median and 90th percentile wait times for resolution of abnormal breast screen with tissue biopsy for asymptomatic women (aged 50–69), by jurisdiction — 2015 screening years
    View this indicator
    Breast cancer

    Incidence rates for breast cancer in women, by stage at diagnosis and province, age-standardized to the 2011 Canadian population — 2015 diagnosis year
    View this indicator
  • About Us
  • Careers
  • Contact
  • Media centre
  • Share your feedback
  • About our new site

  • Français Language toggle.

Other related sites:

  • Canadian Partnership for Tomorrow’s Health
  • Canadian Cancer Research Alliance
  • Canadian Cancer Trials
  • facebook
  • twitter
  • youtube
  • linkedin
    CPAC Logo

    Questions about cancer?

    For information about cancer treatment and support for patients, please contact the Canadian Cancer Society at 1-888-939-3333 or by completing this online form.

  • AODA compliance
  • Privacy policy
  • Terms of use
  • FAQ
  • Site map
  • About this site
© Canadian Partnership Against Cancer Corporation